Ben, I am honored to be part of this story and I marvel at the connections you eloquently described. Kim will always hold a piece of my heart, and it grows even more realizing through your words our connection. I did not know she too was hopeful for AG-120. Long before the drug ever got the name Tibsovo, I was following the promise of a small Boston company whose theme to find “the other side of possible”. This was my mantra and guided me through my own research, hoping to not only give back but also “fight cancer with my pipette”. Though cancer is sad and demotivating, I remember those who influenced my life, their stories giving me strength. Meeting you and Kim, building a friendship through these years, is one of the most special relationships I am honored to have. Bearing witness to this revolutionary change in cancer treatment, as both a scientist and a patient, is one of the highest accolades of my life. The top being a mother.
Thank you for your words, I will cherish this always.
I am merely telling part of you story through my eyes. Thank you for living life in such manner that helps us learn what it means to contribute a verse!
Thank you for also correcting my misattribution on CGRP cloning, with integrity and grace, and that it was first done by Aiyar Nampo. I've made the change and noted it in the footnotes.
As a note to myself, a friend is looking for treatment options for IDH2 positive AML in the EU. It turns out that enasidinib, Agios' FDA approved IDH2 inhibitor, is not approved in the EU, making it difficult for EU residents to get treatment, despite its positive patient benefit. Here are some additional idh1/2 combo inhibitors in development, covered in this paper, that might be enrolling patients. https://tinyurl.com/3fhprwdv
Ben, I am honored to be part of this story and I marvel at the connections you eloquently described. Kim will always hold a piece of my heart, and it grows even more realizing through your words our connection. I did not know she too was hopeful for AG-120. Long before the drug ever got the name Tibsovo, I was following the promise of a small Boston company whose theme to find “the other side of possible”. This was my mantra and guided me through my own research, hoping to not only give back but also “fight cancer with my pipette”. Though cancer is sad and demotivating, I remember those who influenced my life, their stories giving me strength. Meeting you and Kim, building a friendship through these years, is one of the most special relationships I am honored to have. Bearing witness to this revolutionary change in cancer treatment, as both a scientist and a patient, is one of the highest accolades of my life. The top being a mother.
Thank you for your words, I will cherish this always.
I am merely telling part of you story through my eyes. Thank you for living life in such manner that helps us learn what it means to contribute a verse!
Thank you for also correcting my misattribution on CGRP cloning, with integrity and grace, and that it was first done by Aiyar Nampo. I've made the change and noted it in the footnotes.
Love you D!
Note to self, as of December 2024, AG-120, AKA tibsovo, has subsequewntly wrecked Dianna's tumor, shrinking it dramatically. Hell to the yeah, D!
As a note to myself, a friend is looking for treatment options for IDH2 positive AML in the EU. It turns out that enasidinib, Agios' FDA approved IDH2 inhibitor, is not approved in the EU, making it difficult for EU residents to get treatment, despite its positive patient benefit. Here are some additional idh1/2 combo inhibitors in development, covered in this paper, that might be enrolling patients. https://tinyurl.com/3fhprwdv